{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.186","value":"2.09"},{"groupId":"OG001","spread":"0.826","value":"5.26"},{"groupId":"OG002","spread":"5.697","value":"23.40"},{"groupId":"OG003","spread":"12.370","value":"45.65"},{"groupId":"OG004","spread":"13.201","value":"68.61"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"8"}],"units":"Participants"}],"title":"Cycle 1 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.731","value":"1.95"},{"groupId":"OG001","spread":"0.014","value":"4.33"},{"groupId":"OG002","spread":"7.106","value":"21.33"},{"groupId":"OG003","spread":"12.544","value":"52.68"},{"groupId":"OG004","spread":"30.406","value":"121.50"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"2"}],"units":"Participants"}],"title":"Cycle 1 Day 22"}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"8"}],"units":"Participants"}],"dispersionType":"Standard Deviation","groups":[{"description":"Participants received MORAb-066 0.1 mg/kg, infusion intravenously, on Days 1, 8, 15, and 22, in each 28-day treatment cycle until disease progression, participant's discontinuation due to unacceptable toxicity, withdrawal by participants, or discontinuation by study physician decision.","id":"OG000","title":"MORAb-066 0.1 mg/kg"},{"description":"Participants received MORAb-066 0.3 mg/kg, infusion intravenously, on Days 1, 8, 15, and 22, in each 28-day treatment cycle until disease progression, the participant discontinuation due to unacceptable toxicity, withdrawal by participants, or discontinuation by study physician decision.","id":"OG001","title":"MORAb-066 0.3 mg/kg"},{"description":"Participants received MORAb-066 1 mg/kg, infusion intravenously, on Days 1, 8, 15, and 22, in each 28-day treatment cycle until disease progression, the participant's discontinuation due to unacceptable toxicity, withdrawal by participants, or discontinuation by study physician decision.","id":"OG002","title":"MORAb-066 1 mg/kg"},{"description":"Participants received MORAb-066 2 mg/kg, infusion intravenously, on Days 1, 8, 15, and 22, in each 28-day treatment cycle until disease progression, the participant's discontinuation due to unacceptable toxicity, withdrawal by participants, or discontinuation by study physician decision.","id":"OG003","title":"MORAb-066 2 mg/kg"},{"description":"Participants received MORAb-066 3 mg/kg, infusion intravenously, on Days 1, 8, 15, and 22, in each 28-day treatment cycle until disease progression, the participant discontinuation due to unacceptable toxicity, withdrawal by participants, or discontinuation by study physician decision.","id":"OG004","title":"MORAb-066 3 mg/kg"}],"paramType":"MEAN","populationDescription":"The pharmacokinetic (PK) analysis set was the group of participants who had sufficient PK data to derive at least one PK parameter. Here, \"Number analyzed\" signifies participants evaluable at a given time points for this outcome measure.","reportingStatus":"POSTED","timeFrame":"Cycle 1 Days 1 and 22: 0-168 hours post-dose (Cycle length=28 days)","title":"Cmax: Maximum Observed Serum Concentration for MORAb-066","type":"SECONDARY","unitOfMeasure":"microgram per milliliter (mcg/mL)"}